Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Juvenile Diabetes Research Foundation | OTHER |
Not provided
Not provided
Not provided
Not provided
The purpose of this research study is to determine the effects of the probiotic, Lactobacillus johnsonii N6.2, on safety, gastrointestinal function, wellness, fecal bacteria and blood biomarkers in healthy individuals.
Healthy adult volunteers from 18-50 years of age will be recruited through the University of Florida and randomly distributed into two groups. This study is divided into 3 phases: baseline, intervention (study treatment) and washout. Participants will receive either the probiotic or placebo during the intervention phases. During the baseline phase, blood and fecal samples will be collected about 1 week before intervention initiation. On the day of a scheduled blood draw, the participant will need to arrive fasted overnight, and a light breakfast will be provided after blood draw. Starting on day 1 of the intervention phase, a second baseline blood sample will be collected and the participant will begin the study intervention (probiotic or placebo). Participants will consume 1 capsule (probiotic or placebo) daily for 8 weeks, and blood and stool samples will be collected and processed (on or around weeks 2, 4 and 8 of the intervention phase). A Fisher Scientific commode specimen collection system will be provided for stool collections. The stool collection kit may be taken home (participants will be asked to drop off the stool within 4 hours of defecation) for fecal sample collection or may use the restroom in the clinical lab at the Food Science and Human Nutrition Building in which kits will be provided for use. In the wash-out phase, participants will not consume the capsule (either the probiotic or placebo), but will provide blood and stool samples (on or around week 12). Throughout the study, participants will provide a total of 5 stool samples and 6 blood samples. Participants will be asked to complete daily and weekly questionnaires throughout all phases of the study, which will ask about quality of life (physical functioning, mental functioning, level of sleep, etc.), gastrointestinal function, and dietary intake. These assessments will be self-reported via online questionnaires. In the event that internet access is not available for a portion of the study, paper copies of the questionnaires may be provided.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Probiotic | Active Comparator | L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks |
|
| Placebo | Placebo Comparator | Encapsulated starch placebo administered for 8 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| L. johnsonii N6.2 | Biological | L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Reporting Adverse Events | The number of participants reporting Adverse Events was reported. | 13 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Composite Measure of Blood Chemistry Profiles | Number of clinically relevant out of range values of the comprehensive metabolic panel and hemogram during intervention through washout period vs baseline. | 13 weeks |
Not provided
Inclusion Criteria:
To participate in the study individuals must
Exclusion Criteria:
To participate in the study individuals must NOT
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wendy J Dahl, PhD | University of Florida | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Florida, Food Science and Human Nutrition Dept | Gainesville | Florida | 32611 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28659913 | Derived | Marcial GE, Ford AL, Haller MJ, Gezan SA, Harrison NA, Cai D, Meyer JL, Perry DJ, Atkinson MA, Wasserfall CH, Garrett T, Gonzalez CF, Brusko TM, Dahl WJ, Lorca GL. Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults. Front Immunol. 2017 Jun 12;8:655. doi: 10.3389/fimmu.2017.00655. eCollection 2017. |
| Label | URL |
|---|---|
| Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Probiotic | L. johnsonii N6.2 in capsule form administered for 8 weeks L. johnsonii N6.2: L. johnsonii N6.2 in capsule form administered for 8 weeks |
| FG001 | Placebo | Encapsulated starch placebo administered for 8 weeks Placebo: Encapsulated starch placebo administered for 8 weeks |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Probiotic | L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks L. johnsonii N6.2: L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks |
| BG001 | Placebo |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants Reporting Adverse Events | The number of participants reporting Adverse Events was reported. | Subjects completing the probiotic and the placebo intervention. | Posted | Count of Participants | Participants | 13 weeks |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Probiotic | L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks L. johnsonii N6.2: L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Sinus Infection | Infections and infestations |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Wendy Dahl Associate Professor | University of Florida | 3522943707 | wdahl@ufl.edu |
Not provided
| ID | Term |
|---|---|
| C100843 | Lacteol |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Biological | Encapsulated starch placebo administered for 8 weeks |
|
Encapsulated starch placebo administered for 8 weeks
Placebo: Encapsulated starch placebo administered for 8 weeks
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Median | Full Range | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Secondary | Composite Measure of Blood Chemistry Profiles | Number of clinically relevant out of range values of the comprehensive metabolic panel and hemogram during intervention through washout period vs baseline. | Subjects completing intervention and final blood draw after 4 week washout period. | Posted | Number | events | 13 weeks |
|
|
|
| 0 |
| 21 |
| 1 |
| 21 |
| EG001 | Placebo | Encapsulated starch placebo administered for 8 weeks Placebo: Encapsulated starch placebo administered for 8 weeks | 0 | 20 | 2 | 20 |
| Fractured clavical | Injury, poisoning and procedural complications |
|
| Dental Abcess | Infections and infestations |
|
Not provided
Not provided